Recurrence of cryptococcal meningitis in HIV-infected patients following immune reconstitution

International Journal of STD and AIDS

Volumn 20, Issue 4, 2009, Pages 274-275

  Seddon, J ^a   Mangeya, N ^a   Miller, Robert F ^b,c   Corbett, E L ^a,c   Ferrand, R A ^a,c  

^a UNIVERSITY OF ZIMBABWE   (Zimbabwe)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Cryptococcal meningitis; Fluconazole; HIV infection; IRIS

Indexed keywords

AMPHOTERICIN B; EFAVIRENZ; FLUCONAZOLE; LAMIVUDINE; NEVIRAPINE; STAVUDINE;

ADOLESCENT; ADULT; ANTIGEN RECOGNITION; ANTIVIRAL THERAPY; ARTICLE; BACKACHE; BACTERIUM CULTURE; BLURRED VISION; CASE REPORT; CD4 LYMPHOCYTE COUNT; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCUS NEOFORMANS; DIARRHEA; DRUG DOSE INCREASE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEVER; GRAND MAL SEIZURE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; LIMB WEAKNESS; LUMBAR PUNCTURE; MALE; NECK PAIN; PRIORITY JOURNAL; RECURRENT DISEASE; TREATMENT DURATION; VIROTHERAPY; VOMITING; WEIGHT REDUCTION;

ADOLESCENT; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; AMPHOTERICIN B; ANTI-HIV AGENTS; ANTIFUNGAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FATAL OUTCOME; FLUCONAZOLE; HIV SEROPOSITIVITY; HIV-1; HUMANS; MALE; MENINGITIS, CRYPTOCOCCAL; RECURRENCE;

EID: 66349099163     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/ijsa.2008.008312     Document Type: Article

References (16)

1. Hakim JG, Gangaidzo IT, Heyderman RS, et al. Impact of HIV infection on meningitis in Harare, Zimbabwe: a prospective study of 406 predominantly adult patients. AIDS 2000;14:1401-1407
2. Saag MS, Graybill RJ, Larsen RA, et al. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis 2000;30:710-718
3. Masur H, Kaplan JE, Holmes KK. Guidelines for preventing opportunistic infections among HIV-infected persons - 2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. Ann Intern Med 2002;137:435-478
4. Brouwer AE, Rajanuwong A, Chierakul W, et al. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet 2004;363:1764-1767 (Pubitemid 38698379)
5. Schaars CF, Meinjtes GA, Morroni C, Post FA, Maartens G. Outcome of AIDS-associated cryptococcal meningitis initially treated with 200 mg/day or 400 mg/day of fluconazole. BMC Infect Dis 2006;97:175-176 (Pubitemid 46277110)
6. Mwaba P, Mwansa J, Chintu C, et al. Clinical presentation, natural history, and cumulative death rates of 230 adults with primary cryptococcal meningitis in Zambian AIDS patients treated under local conditions. Postgrad Med J 2001;77:769-773 (Pubitemid 33116512)
7. Kambugu A, Meya DB, Rhein J, et al. Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy. Clin Infect Dis 2008;46:1694-1701
8. Mussini C, Pezzotti P, Miro JM, et al. Discontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with highly active antiretroviral therapy: an international observational study. Clin Infect Dis 2004;38:565-571 (Pubitemid 38250968)
9. Vibhagool A, Sungkanuparph S, Mootsikapun P, et al. Discontinuation of secondary prophylaxis for cryptococcal meningitis in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy: a prospective, multicenter, randomized study. Clin Infect Dis 2003;36:1329-1331 (Pubitemid 36629945)
10. Kirk O, Reiss P, Uberti-Foppa C, et al. Safe interruption of maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapy. Ann Intern Med 2002;137:239-250
11. Heyderman RS, Gangaidzo IT, Hakim JG, et al. Cryptococcal meningitis in human immunodeficiency virus-infected patients in Harare, Zimbabwe. Clin Infect Dis 1998;26:284-289 (Pubitemid 28083935)
12. Bicanic T, Meintjes G, Wood R, et al. Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole. Clin Infect Dis 2007;45:76-80 (Pubitemid 46984619)
13. Saag MS, Powderly WG, Cloud GA, et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N Engl J Med 1992;326:83-89
14. Larsen RA, Leal MA, Chan LS. Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS. A randomized trial. Ann Intern Med 1990;113:183-187 (Pubitemid 20242293)
15. King MD, Perlino CA, Cinnamon J, Jernigan JA. Paradoxical recurrent meningitis following therapy of cryptococcal meningitis: an immune reconstitution syndrome after initiation of highly active antiretroviral therapy. Int J STD AIDS 2002;13:724-726
16. Boelaert JR, Godderis KH, Vanopdenbosch LJ, Casselman JW. Relapsing meningitis caused by persistent cryptococcal antigens and immune reconstitution after the initiation of highly active antiretroviral therapy. AIDS 2004;18:1223-1224 (Pubitemid 38738529)